Related Experiment Video
Updated: Jun 2, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia
1Division of Tumour Biology, The Institute of Cancer Research, London, UK.
Abstract:
ABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-ABL(T315I) mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer Cell, that "switch-control" inhibitors block BCR-ABL(T315I) activity by preventing ABL from switching from the inactive to active conformation.
Related Concept Videos
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Drugs that Destabilize Microtubules
